Drugs / Plenvu
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | PLENVU | — | 2018-05-04 | fda.gov ↗ |
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03437265 | Sep → Oct 2020 | — | Norgine | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07218523 | Dec 2025 → Jan 2027 expected | — | Norgine | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05436054 | Oct 2022 → Dec 2025 overdue | colonic disorder | Aalborg University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04297423 | Mar 2020 → Jun 2022 | colorectal cancer | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05242562 | May 2022 → Feb 2023 | colorectal cancer, polyp of colon | Radboud University Medical Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plenvu | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04297423 ↗ |
| Route | Oral | “Oral administration of 1 sachet (115.96 g) PLENVU Dose 1” NCT03437265 ↗ |